Free Trial
NASDAQ:AVTX

Avalo Therapeutics Q2 2024 Earnings Report

Avalo Therapeutics logo
$9.34 -0.31 (-3.21%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$9.30 -0.04 (-0.43%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalo Therapeutics EPS Results

Actual EPS
-$14.07
Consensus EPS
-$6.70
Beat/Miss
Missed by -$7.37
One Year Ago EPS
N/A

Avalo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avalo Therapeutics Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Sunday, August 11, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Avalo Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Avalo Therapeutics Earnings Headlines

Avalo Therapeutics to Participate in Upcoming Investor Conferences
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
See More Avalo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalo Therapeutics and other key companies, straight to your email.

About Avalo Therapeutics

Avalo Therapeutics (NASDAQ:AVTX), a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

View Avalo Therapeutics Profile

More Earnings Resources from MarketBeat